Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 3/10

vs
industry
vs
history
Cash to Debt 0.83
EXEL's Cash to Debt is ranked lower than
83% of the 952 Companies
in the Global Biotechnology industry.

( Industry Median: 49.03 vs. EXEL: 0.83 )
Ranked among companies with meaningful Cash to Debt only.
EXEL' s Cash to Debt Range Over the Past 10 Years
Min: 0.21  Med: 1.29 Max: N/A
Current: 0.83
Equity to Asset -0.39
EXEL's Equity to Asset is ranked lower than
95% of the 698 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. EXEL: -0.39 )
Ranked among companies with meaningful Equity to Asset only.
EXEL' s Equity to Asset Range Over the Past 10 Years
Min: -0.76  Med: 0.13 Max: 0.8
Current: -0.39
-0.76
0.8
F-Score: 6
Z-Score: -3.29
M-Score: -2.87
WACC vs ROIC
14.29%
-617.25%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating margin (%) -198.20
EXEL's Operating margin (%) is ranked lower than
59% of the 743 Companies
in the Global Biotechnology industry.

( Industry Median: -85.53 vs. EXEL: -198.20 )
Ranked among companies with meaningful Operating margin (%) only.
EXEL' s Operating margin (%) Range Over the Past 10 Years
Min: -893.86  Med: -145.27 Max: 30.91
Current: -198.2
-893.86
30.91
Net-margin (%) -265.24
EXEL's Net-margin (%) is ranked lower than
63% of the 743 Companies
in the Global Biotechnology industry.

( Industry Median: -80.71 vs. EXEL: -265.24 )
Ranked among companies with meaningful Net-margin (%) only.
EXEL' s Net-margin (%) Range Over the Past 10 Years
Min: -1069.42  Med: -120.52 Max: 26.14
Current: -265.24
-1069.42
26.14
ROA (%) -49.52
EXEL's ROA (%) is ranked lower than
69% of the 955 Companies
in the Global Biotechnology industry.

( Industry Median: -27.67 vs. EXEL: -49.52 )
Ranked among companies with meaningful ROA (%) only.
EXEL' s ROA (%) Range Over the Past 10 Years
Min: -64.98  Med: -32.09 Max: 20.08
Current: -49.52
-64.98
20.08
ROC (Joel Greenblatt) (%) -8255.33
EXEL's ROC (Joel Greenblatt) (%) is ranked lower than
84% of the 915 Companies
in the Global Biotechnology industry.

( Industry Median: -358.44 vs. EXEL: -8255.33 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
EXEL' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -8255.33  Med: -472.6 Max: 766.96
Current: -8255.33
-8255.33
766.96
Revenue Growth (3Y)(%) -15.60
EXEL's Revenue Growth (3Y)(%) is ranked lower than
70% of the 481 Companies
in the Global Biotechnology industry.

( Industry Median: 4.40 vs. EXEL: -15.60 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
EXEL' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -61.3  Med: -0.4 Max: 25.7
Current: -15.6
-61.3
25.7
EBITDA Growth (3Y)(%) -7.30
EXEL's EBITDA Growth (3Y)(%) is ranked lower than
59% of the 508 Companies
in the Global Biotechnology industry.

( Industry Median: 1.50 vs. EXEL: -7.30 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
EXEL' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -44.8  Med: -5.2 Max: 17.9
Current: -7.3
-44.8
17.9
EPS Growth (3Y)(%) -4.20
EXEL's EPS Growth (3Y)(%) is ranked higher than
50% of the 501 Companies
in the Global Biotechnology industry.

( Industry Median: -3.60 vs. EXEL: -4.20 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
EXEL' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -42.1  Med: -6.8 Max: 16.1
Current: -4.2
-42.1
16.1
» EXEL's 10-Y Financials

Financials (Next Earnings Date: Est. 2016-11-10)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q3 2015

EXEL Guru Trades in Q3 2015

Charles Brandes 25,400 sh (unchged)
» More
Q4 2015

EXEL Guru Trades in Q4 2015

Jim Simons 551,350 sh (New)
Charles Brandes 14,000 sh (-44.88%)
» More
Q1 2016

EXEL Guru Trades in Q1 2016

Paul Tudor Jones 63,482 sh (New)
Jim Simons 1,008,919 sh (+82.99%)
Charles Brandes Sold Out
» More
Q2 2016

EXEL Guru Trades in Q2 2016

Steven Cohen 2,025,400 sh (New)
Joel Greenblatt 21,735 sh (New)
Jim Simons Sold Out
Paul Tudor Jones 31,445 sh (-50.47%)
» More
» Details

Insider Trades

Latest Guru Trades with EXEL

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology
Compare:NAS:CBPO, NAS:GLPG, OTCPK:BTGGF, NYSE:XON, NAS:JUNO, NAS:ACAD, NAS:RARE, OTCPK:SOLTF, NAS:TECH, NAS:SRPT, NAS:ICPT, NAS:KITE, NAS:BLUE, OTCPK:LBTSF, NAS:IONS, NAS:ARIA, NAS:NKTR, NAS:LGND, OTCPK:ABCZY, NYSE:PBYI » details
Traded in other countries:EX9.Germany,
Exelixis Inc is a biotechnology company that develops small molecule therapies for the treatment of cancer.

Exelixis Inc incorporated in November, 1994. It is a biotechnology company which develops small molecule therapies to treat cancer. Its two advanced assets, COMETRIQ "cabozantinib", its wholly-owned inhibitor of multiple receptor tyrosine kinases, and cobimetinib "GDC-0973/XL518", a potent, highly selective inhibitor of MEK, which it out-licensed to Genentech, Inc. a wholly-owned member of the Roche Group, or Genentech, are currently the subject of six ongoing phase 3 pivotal trials. Cabozantinib is being evaluated in a development program, including two ongoing phase 3 pivotal trials in metastatic castration-resistant prostate cancer or CRPC, an ongoing phase 3 pivotal trial in metastatic renal cell cancer or RCC, and an ongoing phase 3 pivotal trial in advanced hepatocellular cancer, or HCC. The programs that the Company runs are Cabozantinib Development Program, CRPC, COMET Pivotal Trials, Combination trials. The Company has development programs in collaboration with Genentech, GlaxoSmithKline, Bristol-Myers Squibb Company, Sanofi, Merck, Daiichi Sankyo Company Limited. It contracts third parties to manufacture raw materials, the active pharmaceutical ingredient, or API, and finished solid dose COMETRIQ products for clinical and commercial uses. The Company follows regulations set forth by FDA and comparable regulatory agencies in state and local jurisdictions and in foreign countries. Federal and state healthcare laws, including fraud and abuse and health information privacy and security laws, are applicable to the Company.

Top Ranked Articles about Exelixis Inc

Top-Performing Non-S&P 500 Stocks of the Year A number of non-S&P stocks beat the best performers of the index
The Standard and Poor’s 500 Index tracks 500 publicly listed companies selected by committee and having three requirements: market caps greater than or equal to $5.3 billion, annual dollar value traded to float-adjusted market cap greater than 1.0 and minimum monthly trading volume of 250,000 shares in the trailing six months of the evaluation date. Read more...

Ratios

vs
industry
vs
history
P/S 46.82
EXEL's P/S is ranked lower than
75% of the 680 Companies
in the Global Biotechnology industry.

( Industry Median: 11.96 vs. EXEL: 46.82 )
Ranked among companies with meaningful P/S only.
EXEL' s P/S Range Over the Past 10 Years
Min: 1.64  Med: 8.35 Max: 47.25
Current: 46.82
1.64
47.25
PFCF 64.18
EXEL's PFCF is ranked lower than
77% of the 119 Companies
in the Global Biotechnology industry.

( Industry Median: 28.24 vs. EXEL: 64.18 )
Ranked among companies with meaningful PFCF only.
EXEL' s PFCF Range Over the Past 10 Years
Min: 3.31  Med: 19.24 Max: 64.18
Current: 64.18
3.31
64.18
POCF 62.30
EXEL's POCF is ranked lower than
78% of the 181 Companies
in the Global Biotechnology industry.

( Industry Median: 22.40 vs. EXEL: 62.30 )
Ranked among companies with meaningful POCF only.
EXEL' s POCF Range Over the Past 10 Years
Min: 3.26  Med: 18.79 Max: 62.3
Current: 62.3
3.26
62.3
EV-to-EBIT -24.95
EXEL's EV-to-EBIT is ranked lower than
99.99% of the 239 Companies
in the Global Biotechnology industry.

( Industry Median: 23.08 vs. EXEL: -24.95 )
Ranked among companies with meaningful EV-to-EBIT only.
EXEL' s EV-to-EBIT Range Over the Past 10 Years
Min: -27.7  Med: -5.6 Max: 35.5
Current: -24.95
-27.7
35.5
EV-to-EBITDA -25.17
EXEL's EV-to-EBITDA is ranked lower than
99.99% of the 258 Companies
in the Global Biotechnology industry.

( Industry Median: 19.61 vs. EXEL: -25.17 )
Ranked among companies with meaningful EV-to-EBITDA only.
EXEL' s EV-to-EBITDA Range Over the Past 10 Years
Min: -35  Med: -6 Max: 28.1
Current: -25.17
-35
28.1
Current Ratio 1.83
EXEL's Current Ratio is ranked lower than
78% of the 925 Companies
in the Global Biotechnology industry.

( Industry Median: 4.42 vs. EXEL: 1.83 )
Ranked among companies with meaningful Current Ratio only.
EXEL' s Current Ratio Range Over the Past 10 Years
Min: 0.84  Med: 2.4 Max: 9.35
Current: 1.83
0.84
9.35
Quick Ratio 1.82
EXEL's Quick Ratio is ranked lower than
74% of the 925 Companies
in the Global Biotechnology industry.

( Industry Median: 4.19 vs. EXEL: 1.82 )
Ranked among companies with meaningful Quick Ratio only.
EXEL' s Quick Ratio Range Over the Past 10 Years
Min: 0.84  Med: 2.4 Max: 9.35
Current: 1.82
0.84
9.35
Days Inventory 196.59
EXEL's Days Inventory is ranked lower than
69% of the 443 Companies
in the Global Biotechnology industry.

( Industry Median: 132.15 vs. EXEL: 196.59 )
Ranked among companies with meaningful Days Inventory only.
EXEL' s Days Inventory Range Over the Past 10 Years
Min: 196.59  Med: 470.86 Max: 471.76
Current: 196.59
196.59
471.76
Days Sales Outstanding 90.90
EXEL's Days Sales Outstanding is ranked lower than
69% of the 586 Companies
in the Global Biotechnology industry.

( Industry Median: 62.03 vs. EXEL: 90.90 )
Ranked among companies with meaningful Days Sales Outstanding only.
EXEL' s Days Sales Outstanding Range Over the Past 10 Years
Min: 4.51  Med: 33.29 Max: 90.9
Current: 90.9
4.51
90.9
Days Payable 423.16
EXEL's Days Payable is ranked higher than
92% of the 412 Companies
in the Global Biotechnology industry.

( Industry Median: 54.96 vs. EXEL: 423.16 )
Ranked among companies with meaningful Days Payable only.
EXEL' s Days Payable Range Over the Past 10 Years
Min: 423.16  Med: 1145.74 Max: 3050.92
Current: 423.16
423.16
3050.92

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -7.50
EXEL's 3-Year Average Share Buyback Ratio is ranked higher than
61% of the 547 Companies
in the Global Biotechnology industry.

( Industry Median: -11.30 vs. EXEL: -7.50 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
EXEL' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -204.5  Med: -11.9 Max: -1.3
Current: -7.5
-204.5
-1.3

Valuation & Return

vs
industry
vs
history
Price/Median PS Value 5.62
EXEL's Price/Median PS Value is ranked lower than
94% of the 615 Companies
in the Global Biotechnology industry.

( Industry Median: 1.00 vs. EXEL: 5.62 )
Ranked among companies with meaningful Price/Median PS Value only.
EXEL' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.24  Med: 1.11 Max: 5.62
Current: 5.62
0.24
5.62
Earnings Yield (Greenblatt) (%) -4.00
EXEL's Earnings Yield (Greenblatt) (%) is ranked higher than
60% of the 921 Companies
in the Global Biotechnology industry.

( Industry Median: -8.80 vs. EXEL: -4.00 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
EXEL' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -4  Med: 12.5 Max: 17.5
Current: -4
-4
17.5

More Statistics

Revenue (TTM) (Mil) $71.47
EPS (TTM) $ -0.84
Beta1.70
Short Percentage of Float14.39%
52-Week Range $3.55 - 15.00
Shares Outstanding (Mil)230.33

Analyst Estimate

Dec16 Dec17
Revenue (Mil $) 162 197
EPS ($) -0.59 -0.43
EPS w/o NRI ($) -0.59 -0.43
EPS Growth Rate
(3Y to 5Y Estimate)
N/A
Dividends Per Share ($)
» More Articles for EXEL

Headlines

Articles On GuruFocus.com
The Best-Performing Non-S&P Stocks of 2015 Dec 30 2015 
5-year lows: Synta Pharmaceuticals Inc, Exelixis Inc, Entropic Communications Inc, and Aeropostale I Dec 28 2014 
5-year lows: National Presto Industries, Ennis Inc, Landauer Inc, and Exelixis Inc. Sep 28 2014 
Weekly 3-Year Low Highlights: UAN, CLD, EXEL, QNST Sep 06 2014 
Five-Year Lows: Rentech Nitrogen Partners LP, SandRidge Permian Trust, Millennial Media Inc., Exelix May 05 2014 
5 Resilient Biotech Stocks to Buy for 2012 Feb 28 2012 
Exelixis Inc. Reports Operating Results (10-K) Feb 22 2011 
Exelixis Inc. (EXEL) CFO Frank Karbe buys 16,500 Shares Aug 25 2010 
Exelixis Inc. Reports Operating Results (10-Q) Aug 05 2010 
Exelixis Inc. Reports Operating Results (10-Q) May 11 2010 

More From Other Websites
Exelixis Provides Update on Timing of Key Cabozantinib Clinical Data Presentation at the ESMO 2016... Sep 20 2016
3 Reasons Momentum Stock Investors Will Love Exelixis (EXEL) Sep 20 2016
Will Exelixis (EXEL) Continue to Surge Higher? Sep 15 2016
Exelixis Wins EU Approval for Cabometyx RCC Treatment (EXEL) Sep 14 2016
Bevy Of Biotech Stocks Healthy; Sarepta, Bluebird, Exelixis Soar Sep 14 2016
Bevy Of Biotech Stocks Healthy; Sarepta, Bluebird, Exelixis Soar Sep 14 2016
Exelixis (EXEL) Stock Advances, EC Approves Kidney Cancer Drug Sep 14 2016
4 stocks to watch Sep 14 2016
Key FDA Decisions and Trial Results Coming in the Next 2 Months Sep 14 2016
European Commission Approves CABOMETYX™ (cabozantinib) Tablets for the Treatment of Advanced Renal... Sep 14 2016
European Commission Approves CABOMETYX™ (cabozantinib) Tablets for the Treatment of Advanced Renal... Sep 14 2016
Exelixis Shares Soar on Cancer Therapies (EXEL) Sep 13 2016
Key FDA Decisions and Trial Results Expected in October Sep 08 2016
Exelixis Reports Interim Analysis of Liver Cancer Trial Data Sep 07 2016
4 stocks to watch Sep 07 2016
ETF’s with exposure to Exelixis, Inc. : September 7, 2016 Sep 07 2016
Exelixis Announces Outcome from First Planned Interim Analysis of the Phase 3 CELESTIAL Trial of... Sep 06 2016
Exelixis Announces Outcome from First Planned Interim Analysis of the Phase 3 CELESTIAL Trial of... Sep 06 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)